FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2573506914> ?p ?o ?g. }

• W2573506914 endingPage "e935" @default.
• W2573506914 startingPage "e935" @default.
• W2573506914 abstract "Stereotactic body radiation therapy (SBRT) is an emerging treatment option for liver tumors unsuitable for ablation or surgery. We report our experience with SBRT in the treatment of liver tumors.Patients with primary or secondary liver cancer were identified in our local SBRT database. Patients were included irrespective of prior liver-directed therapies. The primary endpoint of our review was in-field local control (LC). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity.From 2009 to 2015, a total of 71 liver lesions in 68 patients were treated with SBRT (three patients had two liver lesions treated). The median age was 71 years (27-89 years). Hepatocellular carcinoma (HCC) was the diagnosis in 23 patients (34%), with the grade of Child-Pugh A (52%), B (39%), or C (nine percent) cirrhosis. Six patients (nine percent) had intrahepatic cholangiocarcinoma (IHC). The remaining 39 patients (57%) had metastatic liver lesions. Colorectal adenocarcinoma was the most common primary tumor type (81%). The median size for HCC, IHC, and metastatic lesions was 5 cm (2-9 cm), 3.6 cm (2-4.9 cm), and 4 cm (1-8 cm), respectively. The median prescribed dose was 45 Gy (16-50 Gy). Median follow-up was 11.5 months (1-45 months). Actuarial one-year in-field LC for HCC and metastatic lesions was 85% and 64% respectively (p= 0.66). At one year, the actuarial rate of new liver lesions was 40% and 26%, respectively, (p=0.58) for HCC and metastases. Only six patients with IHC were treated with SBRT in this study - in these patients, one-year LC was 78% with new liver lesions in 53%. The SBRT treatments were well tolerated. The side effects included common criteria for adverse events (CTCAE) v4 grade 1 acute gastrointestinal toxicity in three patients, grade 3 nausea in one patient, and grade 3 acute dermatitis in another patient. Two patients had grade 5 toxicity. Radiation pneumonitis was observed in one patient two months post-SBRT treatment, and another patient was suspected to have had radio-induced liver disease (RILD) two months after SBRT. No late toxicity was seen.SBRT is a well-tolerated and effective alternative treatment option for selected patients with primary and metastatic liver tumors." @default.
• W2573506914 created "2017-01-26" @default.
• W2573506914 creator A5001041858 @default.
• W2573506914 creator A5008392506 @default.
• W2573506914 creator A5022553681 @default.
• W2573506914 creator A5022614350 @default.
• W2573506914 creator A5022871095 @default.
• W2573506914 creator A5026667222 @default.
• W2573506914 creator A5029517342 @default.
• W2573506914 creator A5057219088 @default.
• W2573506914 creator A5064363717 @default.
• W2573506914 creator A5065191119 @default.
• W2573506914 creator A5077574965 @default.
• W2573506914 date "2016-12-20" @default.
• W2573506914 modified "2023-10-01" @default.
• W2573506914 title "Stereotactic Body Radiotherapy for Inoperable Liver Tumors: Results of a Single Institutional Experience." @default.
• W2573506914 cites W1970090414 @default.
• W2573506914 cites W1984572478 @default.
• W2573506914 cites W1992421431 @default.
• W2573506914 cites W2002901680 @default.
• W2573506914 cites W2006407899 @default.
• W2573506914 cites W2015597596 @default.
• W2573506914 cites W2022149321 @default.
• W2573506914 cites W2022980644 @default.
• W2573506914 cites W2039467075 @default.
• W2573506914 cites W2039955225 @default.
• W2573506914 cites W2046338266 @default.
• W2573506914 cites W2055407227 @default.
• W2573506914 cites W2058702789 @default.
• W2573506914 cites W2065410841 @default.
• W2573506914 cites W2067581536 @default.
• W2573506914 cites W2077632698 @default.
• W2573506914 cites W2102214233 @default.
• W2573506914 cites W2113248775 @default.
• W2573506914 cites W2118783371 @default.
• W2573506914 cites W2118813559 @default.
• W2573506914 cites W2119442895 @default.
• W2573506914 cites W2133685049 @default.
• W2573506914 cites W2165322374 @default.
• W2573506914 cites W2165697796 @default.
• W2573506914 cites W2171673899 @default.
• W2573506914 cites W2172053487 @default.
• W2573506914 cites W360836421 @default.
• W2573506914 doi "https://doi.org/10.7759/cureus.935" @default.
• W2573506914 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5258195" @default.
• W2573506914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28123916" @default.
• W2573506914 hasPublicationYear "2016" @default.
• W2573506914 type Work @default.
• W2573506914 sameAs 2573506914 @default.
• W2573506914 citedByCount "8" @default.
• W2573506914 countsByYear W25735069142017 @default.
• W2573506914 countsByYear W25735069142018 @default.
• W2573506914 countsByYear W25735069142019 @default.
• W2573506914 countsByYear W25735069142020 @default.
• W2573506914 countsByYear W25735069142021 @default.
• W2573506914 countsByYear W25735069142022 @default.
• W2573506914 crossrefType "journal-article" @default.
• W2573506914 hasAuthorship W2573506914A5001041858 @default.
• W2573506914 hasAuthorship W2573506914A5008392506 @default.
• W2573506914 hasAuthorship W2573506914A5022553681 @default.
• W2573506914 hasAuthorship W2573506914A5022614350 @default.
• W2573506914 hasAuthorship W2573506914A5022871095 @default.
• W2573506914 hasAuthorship W2573506914A5026667222 @default.
• W2573506914 hasAuthorship W2573506914A5029517342 @default.
• W2573506914 hasAuthorship W2573506914A5057219088 @default.
• W2573506914 hasAuthorship W2573506914A5064363717 @default.
• W2573506914 hasAuthorship W2573506914A5065191119 @default.
• W2573506914 hasAuthorship W2573506914A5077574965 @default.
• W2573506914 hasConcept C126322002 @default.
• W2573506914 hasConcept C126838900 @default.
• W2573506914 hasConcept C203092338 @default.
• W2573506914 hasConcept C2777214474 @default.
• W2573506914 hasConcept C2778019345 @default.
• W2573506914 hasConcept C535046627 @default.
• W2573506914 hasConcept C71924100 @default.
• W2573506914 hasConcept C90924648 @default.
• W2573506914 hasConceptScore W2573506914C126322002 @default.
• W2573506914 hasConceptScore W2573506914C126838900 @default.
• W2573506914 hasConceptScore W2573506914C203092338 @default.
• W2573506914 hasConceptScore W2573506914C2777214474 @default.
• W2573506914 hasConceptScore W2573506914C2778019345 @default.
• W2573506914 hasConceptScore W2573506914C535046627 @default.
• W2573506914 hasConceptScore W2573506914C71924100 @default.
• W2573506914 hasConceptScore W2573506914C90924648 @default.
• W2573506914 hasIssue "12" @default.
• W2573506914 hasLocation W25735069141 @default.
• W2573506914 hasOpenAccess W2573506914 @default.
• W2573506914 hasPrimaryLocation W25735069141 @default.
• W2573506914 hasRelatedWork W2026902286 @default.
• W2573506914 hasRelatedWork W2033489395 @default.
• W2573506914 hasRelatedWork W2148441798 @default.
• W2573506914 hasRelatedWork W2266860383 @default.
• W2573506914 hasRelatedWork W2324406516 @default.
• W2573506914 hasRelatedWork W2362520236 @default.
• W2573506914 hasRelatedWork W2373584996 @default.
• W2573506914 hasRelatedWork W2944853520 @default.
• W2573506914 hasRelatedWork W3030449887 @default.
• W2573506914 hasRelatedWork W3091367366 @default.

• next